<DOC>
	<DOCNO>NCT01288391</DOCNO>
	<brief_summary>This trial conduct Europe Japan . The aim trial ass safety pharmacokinetics ( rate body eliminate trial drug ) single dose NNC128-0000-2011 , administer i.v . ( intravenously ) haemophilia patient .</brief_summary>
	<brief_title>Investigating Safety Pharmacokinetics 2 Different Single Doses NNC128-0000-2011 Haemophilia A B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients diagnose haemophilia A B ( without inhibitor irrespective severity ) base medical record Japan : A legally acceptable representative ( LAR ) require patient 18 19 year Body weight less equal 100.0 kg Body Mass Index ( BMI ) less equal 30.0 kg/m^2 Known suspect allergy trial product ( ) relate product ( include rFVIIa ) Previous participation trial define administration trial product The receipt investigational product within 30 day prior trial start ( screen ) Congenital acquire coagulation disorder haemophilia A B Receipt Immune Tolerance Induction ( ITI ) within last 30 day prior screen Any surgery within 30 day prior screen Planned surgery within trial period Platelet count 50,000 platelets/mcL ( base medical record within last 1 month laboratory result screen ) Prothrombin time ( PT ) 4 time Upper limit normal ( ULN ) International normalise ratio ( INR ) great 1.7 Hepatic dysfunction severe hepatic disease evaluate investigator ( trial physician ) Renal dysfunction ( dialysis ) and/or creatinine level equal 20 % upper normal limit ( accord medical record laboratory result screen ) Advanced atherosclerotic disease ( defined know history ischemic heart disease , ischemic stroke , etc . ) Any disease , condition , medication , accord investigator 's ( trial physician ) judgement , could imply potential hazard patient interfere trial participation trial outcome Mental incapacity , unwillingness cooperate , language barrier preclude adequate understanding cooperation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>